China Expansion For U.S. Biotechnology FirmMarch 22, 2013 | By Supply Chain Editor | Print | Email This Page
Two joint ventures in China have been announced for Catalent Pharma Solutions' Softgel Technologies and Clinical Supply Solutions businesses, respectively.
Catalent has agreed to acquire, pending regulatory approvals, a majority share in Haining-based, privately held Zhejiang Jiang Yuan Tang Biotechnology Company Ltd. The business produces nutritional softgel products for Chinese and Asia Pacific markets, and employs 120 staff. Catalent intends to work with regulators for future expansion into OTC and prescription softgel manufacturing in China.
In the second announcement, Catalent and ShangPharma Corporation, a China-based pharmaceutical and biotechnology research and development outsourcing company, have formed a joint-venture called Catalent (Shanghai) Clinical Trial Supplies Company Ltd. A new 31,000 sq. ft. facility in Shanghai, which is currently under construction, will be the first in China to provide end-to-end solutions for clinical trial supplies, including comparator sourcing, primary and secondary packaging and labeling, and storage and distribution.
The company intends to make additional investments in these two facilities over the next several years to broaden its offerings in the Chinese market.
No other terms of the transactions have been disclosed.